✦ LIBER ✦

Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection

✍ Scribed by David Boutolleau; Claire Deback; Céline Bressollette-Bodin; Shaida Varnous; Nathalie Dhedin; Benoît Barrou; Jean-Paul Vernant; Iradj Gandjbakhch; Berthe-Marie Imbert-Marcille; Henri Agut

Book ID: 113457884
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 165 KB
Volume: 81
Category: Article
ISSN: 0166-3542
DOI: 10.1016/j.antiviral.2008.11.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Question of using valganciclovir for cyt

Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients

✍ Ashok Jain; Ravi Mohanka; Mark Orloff; Peter Abt; Charlotte Ryan; Adel Bozorgzad 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

We read the article by Park et al. with great interest. 1 The authors retrospectively studied the efficacy of low-dose oral valganciclovir (n ϭ 49) compared with the standard dose of ganciclovir (n ϭ 60) for the prevention of cytomegalovirus (CMV) disease in adult liver transplant recipients. The au

Clinical Utility of Cytomegalovirus (CMV

Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R− Transplant Recipients

✍ Atul Humar; Tony Mazzulli; George Moussa; Raymund R. Razonable; Carlos V. Paya; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

238Oral (PO) Valganciclovir (VGC) for pr

238Oral (PO) Valganciclovir (VGC) for preemptive therapy of Cytomegalovirus (CMV) Antigenemia (AG) in hematopoietic stem cell transplant (HSCT) recipients

✍ H.L. Leather; C.L. Meyer; J.R. Wingard 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Determination, validation and standardiz

Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection

✍ C. Martín-Gandul; P. Pérez-Romero; M. Sánchez; G. Bernal; G. Suárez; M. Sobrino; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 313 KB

Oral Ganciclovir in the Prevention of Cy

Oral Ganciclovir in the Prevention of Cytomegalovirus Infection in Postkidney Transplant “CMV at Risk” Recipients: A Controlled, Comparative Study of Two Regimens (750 mg Bid and 500 mg Bid)

✍ N Ahsan; M.J Holman; L Sonderbye; E Langhoff; H.C Yang 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 144 KB

PIN83 Cost-Effectiveness and Cost-Utilit

PIN83 Cost-Effectiveness and Cost-Utility analysis of 200 Days Prophylaxis of Cytomegalovirus (CMV) infections in High Risk (D+/R-) Kidney Transplant Recipients in Poland

✍ P. Kawalec; P. Holko; M. Boratynska; M. Glyda; E. Ignacak; M. Russel-Szymczyk; M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB